RxDoctor Payments Data

Cynthia Gavilanes, PA

Physician Assistant · Pembroke Pines, FLNPI 1629178983

Payments from drug & device makers

$7,472in general payments, 2019–2025

Across 326 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Myriad Genetic Laboratories, Inc.$871
  • Boston Scientific$550
  • Astellas Pharma US Inc$484
  • Axonics, Inc.$476
  • Bayer$435
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$3985%
  • Travel & lodging$4506%
  • Food & beverage$6,26384%
  • Education$3625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,472 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$38,316
Medicare patients
141
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide39$578,423
XtandiEnzalutamide22$294,948
Lupron DepotLeuprolide Acetate32$191,532
GemtesaVibegron149$161,419
Abiraterone Acetate46$133,844
MyrbetriqMirabegron98$77,107
XgevaDenosumab12$36,548
TrelstarTriptorelin Pamoate14$35,701
EligardLeuprolide Acetate18$23,971
Silodosin103$12,349
Tamsulosin Hcl745$9,450
Methenamine Hippurate128$8,377
FirmagonDegarelix Acetate16$7,550
Solifenacin Succinate32$2,906
Dutasteride106$2,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,510$578,42339 claims
Astellas Pharma US IncXtandi, Myrbetriq$484$372,055120 claims
AbbVieLupron Depot$290$191,53232 claims
Sumitomo Pharma America, Inc.Gemtesa$257$161,419149 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$414$133,84446 claims
Verity Pharmaceuticals Inc.Trelstar$255$35,70114 claims
Tolmar Pharmaceuticals, Inc.Eligard$105$23,97118 claims
Ferring Pharmaceuticals Inc.Firmagon$68$7,55016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →